CClinicalTrials.gg
RecruitingNCT04426448Updated Jul 30, 2025

Assessment of a Brief Post Traumatic Stress Disorder Intervention for Use in Botswana

An interventional study of Brief Relaxation, Education And Trauma HEaling in Post Traumatic Stress Disorder, sponsored by University of Botswana. Recruiting at 1 site in Botswana. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by University of Botswana · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to culturally adapt a brief psychological intervention for Post-Traumatic Stress Disorder (PTSD) and assess its efficacy, feasibility, and acceptability in a pilot trial. The intervention has been shown to be efficacious among individuals with comorbid severe mental illness (SMI) and PTSD.

The study will be conducted in three phases. The first phase will determine a description of trauma and responses to traumatic experiences among patients with severe mental illness. The first phase of the study will also determine participants' and mental health care providers' perceptions of suitable PTSD interventions in this middle-income context. The findings will then be used to culturally adapt the brief intervention in the second phase. A pilot trial will be conducted in the third phase of the study.

Participants with comorbid SMI and PTSD will be randomized into two groups (n= 20 intervention group, n= 20 control group). Outcomes of the intervention such as the severity of PTSD symptoms, knowledge about PTSD will be assessed at baseline and at different timelines during the study.

This study will fill the knowledge gap on trauma and its consequences among individuals with severe mental illness in Botswana, it will also contribute to the improvement of clinical practice in the management of PTSD and SMI.

Read the detailed description

Study participants will be recruited from Sbrana Psychiatric Hospital, the only referral psychiatric hospital in Botswana. The hospital population is representative of the culturally diverse Botswana nation because patients with severe mental illness from the entire country are admitted to the hospital. Forty participants (40) will be recruited and randomized to receive the Brief Relaxation, Education, And Trauma HEaling (BREATHE) intervention or treatment as usual.

The intervention will be delivered by the Principal Investigator who has received training from the intervention developer. Supervision will be provided telephonically.

The BREATHE intervention will be delivered weekly for each participant for a total of three weeks and 4 participants will be enrolled per group resulting in a total of 5 groups. The estimated period of intervention delivery and data collection is therefore expected to last for a period of \~15 weeks.

Outcomes such as anxiety, depressive and PTSD Symptoms, and knowledge about PTSD will be assessed before participants receive the intervention, weekly (following each treatment session), month one and month three after treatment completion. Assessment of feasibility and acceptability will be done at treatment completion with the intervention group. Participants on the control arm will receive outcome measures at the same time points as those receiving the intervention. The investigators will utilize an objective assessment of skin conductance which has been shown to be greater in individuals with PTSD than in individuals without PTSD and similarly increased during a trauma interview in individuals with PTSD compared to individuals who do not have PTSD.

02

Conditions studied

  • Post Traumatic Stress Disorder
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Able to understand Setswana or English
  • The patient must meet the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria for any SMI as categorized for this study (schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar mood disorder, and severe depressive disorder)
  • The patient should meet the criteria for Post-Traumatic Stress Disorder as assessed with the Post Traumatic Checklist-5 (PCL-5)

Exclusion criteria

Exclusion Criteria:

  • Currently engaged in psychotherapy for PTSD
  • On pharmacotherapy management of PTSD (to control for medication effects on PTSD symptoms)
  • Inability to understand informed consent
  • Inability to respond to interview questions
  • Patients who have suicidal ideation and history of a suicide attempt within the past 6 months
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Participants will receive the BREATHE intervention for three weeks

    Behavioral: Brief Relaxation, Education And Trauma HEaling

  • No intervention
    Control group

    The participants will receive treatment as usual

Interventions

  • BehavioralBrief Relaxation, Education And Trauma HEaling

    A three-week psychological intervention for PTSD which comprise psychoeducation and breathing retraining to manage anxiety symptoms

05

What researchers measure

Primary outcomes

  1. Post Traumatic Checklist-5

    Mean Change from Baseline in the severity of PTSD symptoms as assessed with the PCL-5. Total scores for the Post Traumatic Checklist-5 range between 0 and 80 with a cut off score of 33 or higher suggesting the patient may benefit from PTSD treatment. Patients with scores lower than 33 may indicate the patient has sub-threshold symptoms of PTSD

    Time frame: baseline, week 1, 2 ,3,

  2. eSense EDA skin conductance device

    Change in physiological arousal as measured with sensors to assess skin conductance

    Time frame: baseline, week 1, 2 ,3,

  3. Mini International Neuropsychiatric Interview (MINI) Plus

    Assessment of symptoms meeting the criteria for PTSD

    Time frame: baseline, week 3, one month and three months post intervention

  4. Consent rates

    to assess the acceptability of the intervention by dividing the number of participants who meet the criteria for PTSD and meet the inclusion criteria for the pilot trial by the number of those who consent to participate in the trial

    Time frame: week 3

  5. Adherence rates

    to assess acceptability; measured by the total number of sessions attended by the participants and the reasons for non-adherence.

    Time frame: week 3

  6. knowledge of PTSD scale (KPTSD)

    mean difference in the scores obtained in the knowledge of PTSD scale. Higher scores indicate more knowledge of PTSD.

    Time frame: baseline, week 1, 2 ,3, one month and three months post intervention

  7. Acceptability of Intervention measure (AIM)

    Calculation of scores in the Acceptability of Intervention measure. Higher scores indicate greater acceptability

    Time frame: week 3

  8. Feasibility of Intervention Measure (FIM)

    calculation of scores in the Feasibility of Intervention Measure. Higher scores indicate greater feasibility

    Time frame: week 3

  9. Patient satisfaction scale

    calculation of scores in the satisfaction scale. Higher satisfaction with the intervention will be indicated by high scores on the patient satisfaction scale

    Time frame: week 3

Secondary outcomes

  1. Patient Health Questionnaire-9 (PHQ-9)

    Mean Change from Baseline in the severity of depressive symptoms as assessed with the PHQ-9

    Time frame: baseline, week 1, 2 ,3, one month and three months post intervention

  2. Clinical Outcomes in Routine Evaluation-Outcome Measure

    Mean difference from Baseline in the severity of psychological distress

    Time frame: baseline, week 3, one month and three months post intervention

  3. Zung self-rating anxiety scale

    Mean Change from Baseline in the severity of anxiety symptoms as assessed with the Zung anxiety rating scale. Total scores in the Zung self rating scale range from 20 to 80, with scores above 26 indicating severe and extremely severe anxiety.

    Time frame: baseline, week 1, 2 ,3, one month and three months post intervention

  4. Post Traumatic Checklist-5

    Mean Change from Baseline in the severity of PTSD symptoms as assessed with the Post Traumatic Checklist-5. A five points difference in the total score is an indication that a patient has responded to treatment and 10 points has been determined as a minimum threshold for determining whether the improvement has clinical utility

    Time frame: one month and three months post intervention

06

Study locations

1 of 1 sites recruiting
  • Sbrana Psychiatric Hospital
    Lobatse, 0000, Botswana
    Recruiting
07

References and documents

Publications

  • Molebatsi K, Ng LC, Chiliza B. A culturally adapted brief intervention for post-traumatic stress disorder in people with severe mental illness in Botswana: protocol for a randomised feasibility trial. Pilot Feasibility Stud. 2021 Sep 3;7(1):170. doi: 10.1186/s40814-021-00904-1. PubMed 34479640 ↗

Individual participant data

Plan to share: Yes — The study will be conducted in fulfillment of a Doctor of Philosophy in Psychiatry degree. De-identified data will be shared with the supervisors

Supporting information: Study protocol, Sap, Csr

08

Registry details

Key details

Study ID
NCT04426448
Lead sponsor
University of Botswana
Collaborators
University of KwaZulu
Responsible party
Keneilwe Molebatsi (Principal Investigator, University of Botswana) — Principal investigator
First posted
Jun 11, 2020
Start date
Jul 8, 2020
Primary completion
Aug 30, 2025 (estimated)
Completion
Aug 30, 2025 (estimated)
Last update
Jul 30, 2025

Study contacts

Keneilwe Molebatsi, MMED (Psychiatry)
Contact
molebatsik@ub.ac..bw
+26777458378
Julia Gaorekwe
Contact
gaorekwej@ub.ac.bw
+2673552900
Keneilwe Molebatsi, MMED (Psych)
principal investigator · University of Botswana

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion